Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

BMRN

Biomarin Pharmaceutical Inc

Feb 06 • 04:00PM ET

58.13

+0.98 1.71 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX SRPT NBIX ALNY BLUE IONS RARE EXEL PRTA

| Held by: VTI IJH VB VBK VXF XBI MDY FBT IBB SPMD

Index	-	P/E	21.78	EPS (ttm)	2.67	Insider Own	1.10%	Shs Outstand	192.10M	Perf Week	2.81%
Market Cap	11.17B	Forward P/E	14.01	EPS next Y	4.15	Insider Trans	0.00%	Shs Float	190.00M	Perf Month	-5.19%
Enterprise Value	10.30B	PEG	0.38	EPS next Q	0.73	Inst Own	96.39%	Short Float	3.89%	Perf Quarter	10.09%
Income	520.42M	P/S	3.62	EPS this Y	11.06%	Inst Trans	-1.68%	Short Ratio	2.76	Perf Half Y	-2.24%
Sales	3.09B	P/B	1.84	EPS next Y	69.09%	ROA	7.20%	Short Interest	7.39M	Perf YTD	-2.19%
Book/sh	31.53	P/C	7.56	EPS next 5Y	36.57%	ROE	9.07%	52W High	73.51 -20.92%	Perf Year	-9.43%
Cash/sh	7.69	P/FCF	13.42	EPS past 3/5Y	- -	ROIC	7.82%	52W Low	50.76 14.52%	Perf 3Y	-50.19%
Dividend Est.	-	EV/EBITDA	10.98	Sales past 3/5Y	15.43% 10.98%	Gross Margin	80.64%	Volatility	2.72% 2.85%	Perf 5Y	-29.96%
Dividend TTM	-	EV/Sales	3.34	EPS Y/Y TTM	60.21%	Oper. Margin	27.73%	ATR (14)	1.59	Perf 10Y	-21.47%
Dividend Ex-Date	-	Quick Ratio	3.10	Sales Y/Y TTM	12.31%	Profit Margin	16.87%	RSI (14)	55.24	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	4.83	EPS Q/Q	-129.25%	SMA20	2.31%	Beta	0.26	Target Price	89.05
Payout	0.00%	Debt/Eq	0.10	Sales Q/Q	5.98%	SMA50	2.72%	Rel Volume	0.61	Prev Close	57.15
Employees	3040	LT Debt/Eq	0.10	Earnings	Oct 27 AMC	SMA200	2.68%	Avg Volume	2.68M	Price	58.13
IPO	Jul 23, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	42.88% -0.17%	Trades		Volume	1,643,456	Change	1.71%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Overweight	$80
Jan-20-26	Upgrade	Canaccord Genuity	Hold → Buy	$98
Dec-03-25	Downgrade	Leerink Partners	Outperform → Market Perform	$60
Nov-06-25	Downgrade	Stifel	Buy → Hold	$61
Sep-08-25	Initiated	H.C. Wainwright	Neutral	$60
Sep-03-25	Initiated	Raymond James	Outperform	$85
Jul-03-25	Resumed	Morgan Stanley	Overweight	$97
Feb-24-25	Upgrade	Oppenheimer	Perform → Outperform	$98
Nov-15-24	Initiated	Wolfe Research	Outperform	$95
Oct-30-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-10-24	Resumed	Raymond James	Outperform	$79
Aug-20-24	Upgrade	Bernstein	Mkt Perform → Outperform	$94 → $110
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral	$104 → $72
May-14-24	Initiated	Evercore ISI	Outperform	$113
Nov-15-23	Initiated	Wells Fargo	Overweight	$100
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform	$82
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy	$120
Jul-27-23	Initiated	Scotiabank	Sector Perform	$95
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$102

Show Previous Ratings

Feb-07-26 04:09AM	Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays (Insider Monkey)
Jan-31-26 05:04AM	Should You Buy BioMarin Pharmaceutical Before Feb. 18? (Motley Fool)
Jan-29-26 04:05PM	BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility (PR Newswire)
Jan-28-26 11:24AM	FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? (Zacks)
06:57AM	Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
07:22AM	Loading…
Jan-27-26 07:22AM	Double-digit Revenue Growth Till 2030 Drives BioMarin's (BMRN) Bullish Thesis (Insider Monkey)
Jan-26-26 07:45AM	BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility (PR Newswire)
Jan-22-26 06:02AM	BioMarin vets form Mendra to modernize rare disease drug development (BioPharma Dive)
Jan-16-26 11:01AM	FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? (Zacks)
09:50AM	Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-15-26 10:08AM	Zacks.com featured highlights include Universal Health Services, PNC Financial Services, Global Payments and BioMarin Pharmaceutical (Zacks)
08:47AM	Buy These 5 Price-to-Book Value Stocks for Gains in 2026 (Zacks)
Jan-14-26 12:25PM	Humana Partners With Atlas to Enhance Cancer Care for Seniors (Zacks)
08:52AM	4 Value Stocks to Buy As Wall Street Weighs Trump Policies (Zacks)
Jan-13-26 11:40AM	BMRN or TARS: Which Is the Better Value Stock Right Now? (Zacks)
09:45AM	Loading…
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
09:40AM	Is BioMarin Pharmaceutical (BMRN) a Great Value Stock Right Now? (Zacks)
05:46AM	BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference (MarketBeat)
Jan-12-26 04:05PM	BioMarin Appoints Arpit Dave Chief Digital and Information Officer (PR Newswire)
09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Jan-08-26 04:05PM	BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA (PR Newswire)
08:30AM	Veeva and BioMarin Form Long-Term Strategic Partnership (PR Newswire)
Jan-05-26 04:26AM	10 Magnificent Stocks That Can Make You Richer in 2026 (Motley Fool)
Jan-01-26 06:29AM	H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver (Insider Monkey)
Dec-30-25 11:54AM	Is BioMarin Pharmaceutical Inc. (BMRN) the Ridiculously Cheap Stock to Buy Now? (Insider Monkey)
Dec-29-25 09:30PM	Rocket Lab, Micron, And CoreWeave Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 22-Dec. 26): Are the Others in Your Portfolio? (Benzinga)
07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.)
Dec-24-25 06:30AM	Spruce Biosciences initiated with an Outperform at Oppenheimer (TipRanks)
Dec-23-25 02:35PM	BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know (StockStory)
Dec-22-25 10:18PM	Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition (Insider Monkey)
09:09PM	Loading…
09:09PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
12:27PM	BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push (Pharmaceutical Technology)
12:15PM	A $4.8 Billion Reason to Buy BioMarin Stock Today (Barchart)
11:46AM	BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B (Zacks)
Dec-20-25 08:13AM	BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus (Insider Monkey)
Dec-19-25 04:32PM	Stocks to Watch Friday Recap: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal) +17.71%
04:17PM	BioMarin Soars 18% After Folding In The $4.8 Billion Takeover Of Amicus (Investor's Business Daily)
04:16PM	Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today (StockStory)
12:41PM	Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play (GuruFocus.com)
11:57AM	BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)
11:01AM	Stocks to Watch Friday: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal)
10:55AM	BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping. (Barrons.com)
09:38AM	Stocks to Watch Friday: Nike, Oracle, FedEx, Sony (The Wall Street Journal)
09:06AM	BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In $4.8 Billion Deal (Investor's Business Daily)
08:13AM	BioMarin to Buy Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)
07:45AM	BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook (PR Newswire)
Dec-15-25 01:16PM	Do Options Traders Know Something About BMRN Stock We Don't? (Zacks)
Dec-11-25 07:44AM	Leerink Cuts BioMarin Pharmaceutical Inc. (BMRN) Price Target to $60, Citing Valuation and Competitive Challenges (Insider Monkey)
Dec-10-25 10:32AM	BioMarin Pharmaceutical Inc. (BMRN) Outlook Lowered By Leerink (Insider Monkey)
Dec-04-25 02:15PM	BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory (Insider Monkey)
Dec-03-25 11:30AM	Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report? (Zacks)
Nov-27-25 11:30AM	Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report? (Zacks)
Nov-24-25 11:00PM	2 Reasons to Like BMRN and 1 to Stay Skeptical (StockStory)
Nov-23-25 10:33PM	Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks (StockStory)
Nov-20-25 11:02PM	BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
06:57AM	Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. (Motley Fool)
Nov-11-25 09:00AM	BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England (PR Newswire)
Nov-04-25 09:36AM	J.P. Morgan Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Nov-03-25 12:31AM	The 5 Most Interesting Analyst Questions From BioMarin Pharmaceutical's Q3 Earnings Call (StockStory)
Oct-31-25 10:28PM	Morgan Stanley Maintains Buy on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Oct-30-25 09:39PM	BioMarin Pharmaceutical (BMRN) Announces Financial Results for Q3 2025 (Insider Monkey)
Oct-29-25 06:11PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
09:00AM	FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria (PR Newswire)
Oct-28-25 04:59PM	Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday (Motley Fool)
02:26PM	BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy (Zacks)
12:24PM	Why is BioMarin Pharmaceutical (BMRN) One of the Most Profitable Biotech Stocks to Buy? (Insider Monkey)
12:10PM	Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today (StockStory)
01:31AM	BMRN Q3 Deep Dive: Product Expansion and Portfolio Shifts Define Outlook (StockStory)
Oct-27-25 11:00PM	BioMarin Pharmaceutical Inc (BMRN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
06:00PM	Compared to Estimates, BioMarin (BMRN) Q3 Earnings: A Look at Key Metrics (Zacks)
05:30PM	BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings Estimates (Zacks)
04:32PM	BioMarin: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	BioMarin Pharmaceutical (NASDAQ:BMRN) Posts Q3 Sales In Line With Estimates (StockStory)
04:03PM	BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update (PR Newswire)
01:55PM	BioMarin, following sluggish sales, to offload hemophilia gene therapy (BioPharma Dive)
Oct-25-25 11:03PM	BioMarin Pharmaceutical (BMRN) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-24-25 12:43AM	3 of Wall Street's Favorite Stocks to Target This Week (StockStory)
Oct-23-25 10:00AM	Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-22-25 04:05PM	BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET (PR Newswire)
Oct-17-25 09:54PM	Cantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Oct-08-25 12:57AM	Where is BioMarin Pharmaceutical (BMRN) Headed According to Analysts? (Insider Monkey)
Oct-06-25 09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
Oct-02-25 09:46AM	Growth and Pipeline Keep BioMarin Pharmaceutical Inc. (BMRN) Attractive for Investors (Insider Monkey)
Oct-01-25 08:08PM	BioMarin Pharmaceutical Inc. (BMRN) Hits Its 52-Week Low (Insider Monkey)
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Sep-30-25 04:01AM	Raymond James Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a $85 PT (Insider Monkey)
Sep-19-25 09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Sep-18-25 12:39PM	BioMarin Pharmaceutical Inc.'s (BMRN) Phenylketonuria Candidate Drug Impresses in Phase 3 Trials (Insider Monkey)
Sep-17-25 02:27PM	BMO Capital Reiterates a Buy on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Sep-16-25 12:37PM	BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory (Insider Monkey)
09:51AM	New Study Results Highlight BioMarin's VOXZOGO Efficacy in Children (Insider Monkey)
Sep-15-25 11:31PM	Reflecting On Therapeutics Stocks' Q2 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) (StockStory)
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Sep-09-25 03:11PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Sep-08-25 02:39PM	Are Options Traders Betting on a Big Move in BioMarin Pharmaceutical Stock? (Zacks)
11:46AM	Why BioMarin Pharmaceutical (BMRN) Stock Is Down Today (StockStory)
09:49AM	Alphabet downgraded, Boeing upgraded: Wall Street's top analyst calls (The Fly)
09:00AM	BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting (PR Newswire)
04:00AM	Inside pharmas race to deliver new treatments for dwarfism (Pharma Voice)
04:00AM	Can drug developers help kids with dwarfism reach new heights? (Pharma Voice)

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burkhart Erin	GVP, Chief Accounting Officer	May 20 '25	Sale	59.31	1,786	105,928	14,173	May 20 05:58 PM
Burkhart Erin	Officer	May 20 '25	Proposed Sale	59.31	1,786	105,928		May 20 09:58 AM
Hubbard Cristin	EVP, Chief Commercial Officer	May 02 '25	Sale	64.92	273	17,723	32,700	May 06 05:07 PM
Hubbard Cristin	Officer	May 02 '25	Proposed Sale	64.92	273	17,723		May 02 10:05 AM
Burkhart Erin	GVP, Chief Accounting Officer	Mar 19 '25	Sale	71.52	1,295	92,618	16,955	Mar 20 07:38 PM
Burkhart Erin	Officer	Mar 19 '25	Proposed Sale	71.52	1,295	92,618		Mar 19 09:36 AM
Guyer Charles Greg	EVP, Chief Technical Officer	Mar 06 '25	Sale	71.28	7,034	501,355	87,655	Mar 07 04:06 PM
Guyer Charles Greg	Officer	Mar 06 '25	Proposed Sale	71.28	7,034	501,359		Mar 06 04:05 PM
Burkhart Erin	GVP, Chief Accounting Officer	Feb 24 '25	Sale	68.38	1,344	91,903	13,105	Feb 25 08:21 PM
Burkhart Erin	Officer	Feb 24 '25	Proposed Sale	68.38	1,344	91,903		Feb 24 10:26 AM

Open in Screener

INCY

Incyte Corp

Feb 06 • 04:00PM ET

108.39

+5.63 5.48 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN GILD IONS BMY MRK JNJ AMGN PFE LLY

| Held by: VTI VOO VB IVV VBK SPY RSP IBB USMV XLV

Index	S&P 500	P/E	18.18	EPS (ttm)	5.96	Insider Own	1.02%	Shs Outstand	196.13M	Perf Week	8.31%
Market Cap	21.28B	Forward P/E	14.08	EPS next Y	7.70	Insider Trans	-13.77%	Shs Float	194.08M	Perf Month	-1.97%
Enterprise Value	18.39B	PEG	0.13	EPS next Q	1.90	Inst Own	103.91%	Short Float	5.56%	Perf Quarter	2.54%
Income	1.19B	P/S	4.42	EPS this Y	527.12%	Inst Trans	2.60%	Short Ratio	5.30	Perf Half Y	38.61%
Sales	4.81B	P/B	4.57	EPS next Y	14.07%	ROA	20.96%	Short Interest	10.80M	Perf YTD	9.74%
Book/sh	23.71	P/C	7.26	EPS next 5Y	105.24%	ROE	30.39%	52W High	112.29 -3.47%	Perf Year	44.02%
Cash/sh	14.92	P/FCF	17.78	EPS past 3/5Y	-66.90% -40.36%	ROIC	25.39%	52W Low	53.56 102.37%	Perf 3Y	26.62%
Dividend Est.	-	EV/EBITDA	13.64	Sales past 3/5Y	12.41% 14.46%	Gross Margin	91.55%	Volatility	3.62% 3.34%	Perf 5Y	19.21%
Dividend TTM	-	EV/Sales	3.82	EPS Y/Y TTM	3563.21%	Oper. Margin	26.10%	ATR (14)	3.56	Perf 10Y	53.61%
Dividend Ex-Date	-	Quick Ratio	3.13	Sales Y/Y TTM	18.09%	Profit Margin	24.69%	RSI (14)	61.37	Recom	2.38
Dividend Gr. 3/5Y	- -	Current Ratio	3.20	EPS Q/Q	287.38%	SMA20	4.52%	Beta	0.83	Target Price	105.81
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	20.05%	SMA50	6.37%	Rel Volume	1.08	Prev Close	102.76
Employees	2617	LT Debt/Eq	0.01	Earnings	Feb 10 BMO	SMA200	28.29%	Avg Volume	2.04M	Price	108.39
IPO	Nov 04, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	40.71% 8.91%	Trades		Volume	2,192,860	Change	5.48%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-05-26	Initiated	H.C. Wainwright	Buy	$135
Jan-20-26	Downgrade	Wells Fargo	Overweight → Equal Weight	$107
Dec-08-25	Upgrade	Mizuho	Neutral → Outperform	$121
Nov-03-25	Upgrade	Guggenheim	Neutral → Buy	$125
Oct-08-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-06-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$89
Aug-01-25	Initiated	Barclays	Overweight	$90
Jun-16-25	Upgrade	Stifel	Hold → Buy	$107
Mar-18-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-18-25	Downgrade	Guggenheim	Buy → Neutral
Dec-17-24	Initiated	UBS	Neutral	$77
Oct-29-24	Upgrade	BofA Securities	Neutral → Buy	$68 → $90
Oct-01-24	Initiated	Wolfe Research	Outperform	$84
Sep-18-24	Downgrade	Truist	Buy → Hold	$83 → $74
Jul-02-24	Downgrade	BMO Capital Markets	Market Perform → Underperform	$52 → $48
May-23-24	Initiated	Deutsche Bank	Hold	$55
Apr-23-24	Initiated	Cantor Fitzgerald	Neutral
Feb-23-24	Initiated	Jefferies	Buy	$81
Feb-14-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-13-23	Upgrade	Leerink Partners	Market Perform → Outperform	$78

Show Previous Ratings

Feb-06-26 08:23AM	Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards? (Zacks) +5.48%
Feb-05-26 10:12AM	Microsoft downgraded, Snap upgraded: Wall Street's top analyst calls (The Fly)
09:15AM	Unveiling Incyte (INCY) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
07:58AM	Here Are Thursdays Top Wall Street Analyst Research Calls: CAVA Group, DigitalOcean, Fox Corp, Jack Henry, Microsoft, Qualcomm, Snap, Zoom Communications, and More (24/7 Wall St.)
Feb-04-26 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
08:55AM	Loading…
08:55AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
08:11AM	TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029 (Insider Monkey)
Feb-03-26 10:00AM	Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
05:56AM	Analysts Differ in Opinion on Jakafi Drug Maker Incyte (INCY) (Insider Monkey)
Jan-30-26 09:29AM	Incyte Announces Positive CHMP Opinion for Zynyz (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) (Business Wire)
Jan-27-26 08:00AM	Incyte to Report Fourth Quarter and Year-End 2025 Financial Results (Business Wire)
Jan-26-26 09:50AM	Here's Why Incyte (INCY) is a Strong Momentum Stock (Zacks)
Jan-23-26 09:40AM	Why Incyte (INCY) is a Top Value Stock for the Long-Term (Zacks)
Jan-20-26 09:36AM	Intel upgraded, Domino's downgraded: Wall Street's top analyst calls (The Fly)
04:20PM	Loading…
Jan-14-26 04:20PM	Why Incyte (INCY) Stock Is Trading Up Today (StockStory)
Jan-13-26 06:13PM	Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity (CNBC TV)
09:03AM	Earnings Preview: What To Expect From Incyte's Report (Barchart)
08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jan-12-26 12:10PM	Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? (Zacks)
05:47AM	Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth (Benzinga)
Jan-09-26 11:40AM	This Biotech Stock Eyes Fresh Entry With 522% Earnings Growth Seen (Investor's Business Daily)
04:00AM	Bull of the Day: Eli Lilly (LLY) (Zacks)
Jan-08-26 09:16AM	Rule Breaker Investing Market Cap Game Show: Is Your Favorite Stock in the Spotlight? (Motley Fool)
Jan-07-26 11:21AM	Incyte (INCY) Stock Is Up, What You Need To Know (StockStory)
08:55AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Jan-06-26 10:19AM	INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma (Zacks)
Jan-05-26 07:30AM	Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi/Minjuvi) as a First-line Treatment for Diffuse Large B-Cell Lymphoma (Business Wire)
Dec-27-25 08:00AM	Palantir, Nvidia Lead 5 Stocks Near Buy Points Heading Into Final Days Of 2025 (Investor's Business Daily)
Dec-22-25 09:03AM	Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
02:44AM	Loading…
02:44AM	Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma (Business Wire)
02:42AM	Incyte Japan Announces Approval of Zynyz (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer (Business Wire)
Dec-18-25 09:30AM	EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi (Zacks)
08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
06:56AM	EC approves Incyte's Minjuvi combo for follicular lymphoma (Pharmaceutical Business Review)
Dec-17-25 11:20AM	Incyte Announces European Commission Approval of Minjuvi (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (Business Wire)
Dec-15-25 08:21AM	Is Incyte Stock Outperforming the Nasdaq? (Barchart)
Dec-12-25 08:30AM	Incyte Announces Change to its Board of Directors (Business Wire)
Dec-11-25 09:40AM	Here's Why Incyte (INCY) is a Strong Value Stock (Zacks)
Dec-09-25 01:23PM	Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack (CNBC TV)
Dec-08-25 04:30PM	Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia (Business Wire) -5.68%
10:30AM	Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status (Zacks)
09:45AM	Incyte Stock Falls Despite FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug (Investor's Business Daily)
07:10AM	Incyte Stock Rises On FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug (Investor's Business Daily)
Dec-07-25 09:30AM	Incytes First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA (Business Wire)
09:30AM	Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025 (Business Wire)
Dec-03-25 04:30PM	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-02-25 09:15AM	Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding (Business Wire)
Nov-27-25 11:30AM	Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-20-25 09:50AM	Why Incyte (INCY) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-19-25 09:41AM	Why Incyte (INCY) is a Top Value Stock for the Long-Term (Zacks)
08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
Nov-17-25 01:00AM	Incyte Announces Positive CHMP Opinion for Minjuvi (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL) (Business Wire)
Nov-14-25 07:30AM	Incyte Stock Outlook: Is Wall Street Bullish or Bearish? (Barchart)
Nov-12-25 01:33PM	Ocular Therapeutix Stock Earns 81 RS Rating (Investor's Business Daily)
Nov-10-25 10:31PM	Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack (StockStory)
Nov-07-25 01:18PM	Halozyme Therapeutics Stock Sees Improved RS Rating (Investor's Business Daily)
Nov-06-25 09:15AM	Incytes Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema (Business Wire)
Nov-05-25 11:01PM	Incyte (INCY): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Nov-04-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
06:18AM	Incyte (INCY) Extends Climb, Hits New High on Bullish Coverage (Insider Monkey)
12:38AM	The 5 Most Interesting Analyst Questions From Incyte's Q3 Earnings Call (StockStory)
Nov-03-25 07:38PM	Analyst Report: Incyte Corporation (Morningstar Research) +8.65%
09:31AM	Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting (Business Wire)
Oct-30-25 03:04PM	Incyte Corp (INCY) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
09:36AM	Analyst Report: Incyte Corporation (Morningstar Research)
08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
Oct-29-25 01:31AM	INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus (StockStory)
Oct-28-25 02:42PM	1 Growth Stock Under $100 to Buy Before It Soars (Barchart)
12:24PM	Bank of America Securities Maintains a Buy on Incyte Corporation (INCY) (Insider Monkey)
12:11PM	Why Incyte (INCY) Stock Is Trading Lower Today (StockStory)
11:09AM	INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales (Zacks)
09:49AM	Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views (Investor's Business Daily)
09:30AM	Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:15AM	Incyte (INCY) Tops Q3 Earnings and Revenue Estimates (Zacks)
07:18AM	Incyte (NASDAQ:INCY) Reports Strong Q3 (StockStory)
07:10AM	Incyte: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Oct-27-25 12:44PM	ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards? (Zacks)
07:30AM	Incyte and Enable Injections Announce Strategic Partnership for enFuse On-Body Delivery System (Business Wire)
Oct-26-25 11:12PM	What To Expect From Incyte's (INCY) Q3 Earnings (StockStory)
Oct-25-25 07:55PM	Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis (Business Wire)
Oct-24-25 09:57AM	Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards? (Zacks)
09:56AM	REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline? (Zacks)
08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
06:45AM	Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial (PR Newswire)
Oct-23-25 08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Oct-22-25 10:00AM	GSK (GSK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-21-25 10:00AM	Incyte (INCY) Earnings Expected to Grow: Should You Buy? (Zacks)
08:55AM	Incyte's Quarterly Earnings Preview: What You Need to Know (Barchart)
Oct-20-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Incyte (INCY) is a Great Choice (Zacks)
09:30AM	Will Positive Regulatory Updates Further Boost INCY Stock? (Zacks)
Oct-19-25 01:30PM	Incyte Announces Phase 1 Results for its TGFR2PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma (Business Wire)
Oct-16-25 01:40PM	Xencor Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
12:26PM	Incyte (INCY) Stock Is Up, What You Need To Know (StockStory)
11:40AM	INCY or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Oct-12-25 06:05PM	Data from Incytes TGFR2PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025 (Business Wire)
Oct-10-25 08:44AM	Abbott to Report Q3 Earnings: Medical Devices Arm in Focus (Zacks)
Oct-08-25 01:05PM	Scholar Rock Holding Stock Scores RS Rating Upgrade (Investor's Business Daily)
11:16AM	TLRY Gears Up to Report Q1 Earnings: Cannabis Recovery in Focus (Zacks)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Issa Mohamed Khairie	EVP, Head of US Oncology	Jan 07 '26	Sale	109.07	10,856	1,184,064	66,132	Jan 08 04:03 PM
Stein Steven H	EVP & Chief Medical Officer	Jan 05 '26	Sale	101.70	15,634	1,589,978	34,203	Jan 07 04:03 PM
MOHAMED ISSA	Officer	Jan 07 '26	Proposed Sale	109.07	10,856	1,184,051		Jan 07 04:01 PM
VIJAY IYENGAR	Officer	Jan 06 '26	Proposed Sale	104.35	95,811	9,998,256		Jan 06 04:05 PM
VIJAY IYENGAR	Officer	Jan 05 '26	Proposed Sale	102.81	16,437	1,689,888		Jan 05 04:34 PM
STEVEN STEIN	Officer	Jan 05 '26	Proposed Sale	101.70	15,634	1,589,995		Jan 05 04:06 PM
Tray Thomas	Principal Accounting Officer	Dec 19 '25	Option Exercise	95.76	2,774	265,638	25,747	Dec 22 08:46 PM
Tray Thomas	Principal Accounting Officer	Dec 19 '25	Sale	100.00	2,774	277,400	22,973	Dec 22 08:46 PM
Tray Thomas	Principal Accounting Officer	Dec 18 '25	Sale	98.25	600	58,950	22,973	Dec 22 08:46 PM
VIJAY IYENGAR	Officer	Dec 19 '25	Proposed Sale	101.73	52,941	5,385,677		Dec 19 04:06 PM
THOMAS R TRAY	Officer	Dec 19 '25	Proposed Sale	100.00	2,774	277,400		Dec 19 04:05 PM
THOMAS R TRAY	Officer	Dec 18 '25	Proposed Sale	98.25	600	58,950		Dec 18 04:12 PM
Morrissey Michael James	EVP, Head of Tech. Operations	Dec 16 '25	Sale	97.29	54,008	5,254,547	31,830	Dec 18 04:11 PM
Morrissey Michael James	EVP, Head of Tech. Operations	Dec 17 '25	Sale	97.26	4,323	420,455	27,507	Dec 18 04:11 PM
MICHAEL MORRISSEY	Officer	Dec 17 '25	Proposed Sale	97.26	4,323	420,455		Dec 17 04:01 PM
VIJAY IYENGAR	Officer	Dec 16 '25	Proposed Sale	98.39	13,388	1,317,245		Dec 16 04:53 PM
MICHAEL MORRISSEY	Officer	Dec 16 '25	Proposed Sale	97.29	54,008	5,254,458		Dec 16 04:15 PM
CHRISTIANA STAMOULIS	Officer	Dec 15 '25	Proposed Sale	97.00	187,690	18,205,930		Dec 15 05:31 PM
Mayes Patrick A	EVP & Chief Scientific Officer	Dec 10 '25	Sale	95.58	5,553	530,756	60,266	Dec 12 04:01 PM
Mayes Patrick A	EVP & Chief Scientific Officer	Dec 11 '25	Sale	94.94	255	24,210	60,011	Dec 12 04:01 PM
PATRICK A MAYES	Officer	Dec 11 '25	Proposed Sale	94.94	255	24,210		Dec 11 04:13 PM
VIJAY IYENGAR	Officer	Dec 10 '25	Proposed Sale	95.51	23,104	2,206,695		Dec 10 05:29 PM
PATRICK A MAYES	Officer	Dec 10 '25	Proposed Sale	95.58	5,553	530,756		Dec 10 04:04 PM
Stein Steven H	EVP & Chief Medical Officer	Dec 02 '25	Sale	102.51	20,105	2,060,964	63,129	Dec 03 04:36 PM
Stein Steven H	EVP & Chief Medical Officer	Dec 01 '25	Sale	102.96	2,559	263,475	100,327	Dec 03 04:36 PM
STEVEN STEIN	Officer	Dec 02 '25	Proposed Sale	102.51	20,105	2,060,978		Dec 02 04:04 PM
STEVEN STEIN	Officer	Dec 01 '25	Proposed Sale	102.96	2,559	263,482		Dec 01 04:05 PM
Tray Thomas	Principal Accounting Officer	Nov 24 '25	Sale	103.00	600	61,800	23,573	Nov 25 04:02 PM
Tray Thomas	Principal Accounting Officer	Nov 21 '25	Sale	102.00	169	17,238	24,173	Nov 25 04:02 PM
THOMAS R TRAY	Officer	Nov 24 '25	Proposed Sale	103.00	600	61,800		Nov 24 04:13 PM
THOMAS R TRAY	Officer	Nov 21 '25	Proposed Sale	102.00	169	17,238		Nov 21 04:17 PM
Denton Sheila A.	EVP & General Counsel	Nov 17 '25	Option Exercise	64.25	278	17,862	26,847	Nov 19 04:08 PM
Denton Sheila A.	EVP & General Counsel	Nov 17 '25	Sale	104.36	278	29,012	26,569	Nov 19 04:08 PM
SHEILA DENTON	Officer	Nov 17 '25	Proposed Sale	104.36	278	29,012		Nov 17 04:01 PM
Hoppenot Herve	Director	Nov 10 '25	Sale	105.46	187,500	19,773,750	329,646	Nov 12 04:06 PM
CHRISTIANA STAMOULIS	Officer	Nov 12 '25	Proposed Sale	109.00	7,442	811,178		Nov 12 04:06 PM
HERVE HOPPENOT	Officer	Nov 10 '25	Proposed Sale	105.46	187,500	19,773,454		Nov 10 06:14 PM
Stein Steven H	EVP & Chief Medical Officer	Nov 05 '25	Option Exercise	93.04	5,233	486,868	108,119	Nov 07 04:01 PM
Stein Steven H	EVP & Chief Medical Officer	Nov 05 '25	Sale	102.20	5,233	534,813	102,886	Nov 07 04:01 PM
Denton Sheila A.	EVP & General Counsel	Nov 04 '25	Option Exercise	58.06	598	34,720	27,167	Nov 06 04:01 PM
Denton Sheila A.	EVP & General Counsel	Nov 04 '25	Sale	101.36	598	60,613	26,569	Nov 06 04:01 PM
STEVEN STEIN	Officer	Nov 05 '25	Proposed Sale	102.20	5,233	534,813		Nov 05 04:37 PM
Heeson Lee	EVP, Head of Incyte Intl	Nov 03 '25	Sale	94.02	3,074	289,017	29,241	Nov 05 04:12 PM
SHEILA DENTON	Officer	Nov 04 '25	Proposed Sale	101.36	598	60,613		Nov 04 04:09 PM
CHRISTIANA STAMOULIS	Officer	Nov 03 '25	Proposed Sale	97.74	22,113	2,161,367		Nov 03 04:11 PM
LEE HEESON	Officer	Nov 03 '25	Proposed Sale	94.02	3,074	289,017		Nov 03 04:02 PM
CHRISTIANA STAMOULIS	Officer	Oct 30 '25	Proposed Sale	94.00	14,986	1,408,684		Oct 30 04:31 PM
BARRY FLANNELLY	Officer	Oct 27 '25	Proposed Sale	91.73	33,452	3,068,539		Oct 27 04:21 PM
Denton Sheila A.	EVP & General Counsel	Oct 15 '25	Option Exercise	64.25	277	17,797	26,846	Oct 17 04:01 PM
Denton Sheila A.	EVP & General Counsel	Oct 15 '25	Sale	85.13	277	23,581	26,569	Oct 17 04:01 PM
BARRY FLANNELLY	Officer	Oct 16 '25	Proposed Sale	92.38	18,495	1,708,609		Oct 16 04:01 PM
SHEILA DENTON	Officer	Oct 15 '25	Proposed Sale	85.13	277	23,581		Oct 15 04:03 PM
Denton Sheila A.	EVP & General Counsel	Oct 02 '25	Option Exercise	58.06	599	34,778	33,799	Oct 06 04:02 PM
Denton Sheila A.	EVP & General Counsel	Oct 03 '25	Sale	85.54	3,501	299,476	26,569	Oct 06 04:02 PM
Denton Sheila A.	EVP & General Counsel	Oct 02 '25	Sale	87.65	599	52,502	33,200	Oct 06 04:02 PM
SHEILA DENTON	Officer	Oct 03 '25	Proposed Sale	85.54	3,501	299,464		Oct 03 04:07 PM
SHEILA DENTON	Officer	Oct 02 '25	Proposed Sale	87.65	599	52,502		Oct 02 04:01 PM
BARRY FLANNELLY	Officer	Sep 18 '25	Proposed Sale	85.26	17,447	1,487,531		Sep 18 05:10 PM
Denton Sheila A.	EVP & General Counsel	Sep 16 '25	Option Exercise	64.25	278	17,862	33,478	Sep 18 04:06 PM
Denton Sheila A.	EVP & General Counsel	Sep 16 '25	Sale	83.15	278	23,116	33,200	Sep 18 04:06 PM
SHEILA DENTON	Officer	Sep 16 '25	Proposed Sale	83.15	278	23,116		Sep 16 04:03 PM
Denton Sheila A.	EVP & General Counsel	Sep 02 '25	Option Exercise	58.06	598	34,720	33,798	Sep 04 04:04 PM
Denton Sheila A.	EVP & General Counsel	Sep 02 '25	Sale	84.97	598	50,812	33,200	Sep 04 04:04 PM
SHEILA DENTON	Officer	Sep 02 '25	Proposed Sale	84.97	598	50,812		Sep 02 04:07 PM
Denton Sheila A.	EVP & General Counsel	Aug 15 '25	Option Exercise	64.25	277	17,797	33,477	Aug 19 04:13 PM
Denton Sheila A.	EVP & General Counsel	Aug 15 '25	Sale	86.81	277	24,046	33,200	Aug 19 04:13 PM
SHEILA DENTON	Officer	Aug 15 '25	Proposed Sale	86.81	277	24,046		Aug 15 04:05 PM
BARRY FLANNELLY	Officer	Aug 13 '25	Proposed Sale	82.51	75,963	6,267,540		Aug 13 04:18 PM
BARRY FLANNELLY	Officer	Aug 12 '25	Proposed Sale	80.00	14,037	1,122,970		Aug 12 04:21 PM
Denton Sheila A.	EVP & General Counsel	Aug 04 '25	Option Exercise	58.06	598	34,720	33,798	Aug 06 04:03 PM
Denton Sheila A.	EVP & General Counsel	Aug 04 '25	Sale	75.77	598	45,310	33,200	Aug 06 04:03 PM
SHEILA DENTON	Officer	Aug 04 '25	Proposed Sale	75.77	598	45,310		Aug 04 04:05 PM
Stein Steven H	EVP & Chief Medical Officer	Jul 21 '25	Sale	67.94	3,706	251,786	102,886	Jul 23 03:56 PM
STEVEN STEIN	Officer	Jul 21 '25	Proposed Sale	67.94	3,706	251,786		Jul 21 04:01 PM
Flannelly Barry P	EVP & General Manager US	Jul 16 '25	Sale	68.36	1,340	91,602	35,149	Jul 17 04:06 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 16 '25	Sale	68.36	983	67,198	40,540	Jul 17 04:05 PM
Denton Sheila A.	EVP & General Counsel	Jul 15 '25	Option Exercise	64.25	3,330	213,952	29,834	Jul 17 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jul 15 '25	Sale	69.86	3,330	232,634	26,504	Jul 17 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jul 16 '25	Sale	68.36	785	53,663	33,200	Jul 17 04:04 PM
VIJAY IYENGAR	Officer	Jul 16 '25	Proposed Sale	68.36	983	67,198		Jul 16 04:07 PM
BARRY FLANNELLY	Officer	Jul 16 '25	Proposed Sale	68.36	1,340	91,602		Jul 16 04:06 PM
Stein Steven H	EVP & Chief Medical Officer	Jul 14 '25	Sale	68.47	14,952	1,023,763	97,466	Jul 16 04:05 PM
SHEILA DENTON	Officer	Jul 16 '25	Proposed Sale	68.36	785	53,663		Jul 16 04:02 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 15 '25	Sale	69.86	1,177	82,225	35,929	Jul 16 04:02 PM
Flannelly Barry P	EVP & General Manager US	Jul 15 '25	Sale	69.86	1,192	83,273	37,630	Jul 16 04:02 PM
BARRY FLANNELLY	Officer	Jul 15 '25	Proposed Sale	69.86	1,192	83,273		Jul 15 04:41 PM
SHEILA DENTON	Officer	Jul 15 '25	Proposed Sale	69.86	3,330	232,634		Jul 15 04:37 PM
VIJAY IYENGAR	Officer	Jul 15 '25	Proposed Sale	69.86	1,177	82,225		Jul 15 04:20 PM
STEVEN STEIN	Officer	Jul 14 '25	Proposed Sale	68.47	14,952	1,023,714		Jul 14 04:03 PM
Flannelly Barry P	EVP & General Manager US	Jul 03 '25	Sale	68.15	10,903	743,039	39,744	Jul 07 04:46 PM
Denton Sheila A.	EVP & General Counsel	Jul 02 '25	Option Exercise	58.06	599	34,778	27,103	Jul 07 04:44 PM
Denton Sheila A.	EVP & General Counsel	Jul 02 '25	Sale	68.61	599	41,097	26,504	Jul 07 04:44 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 03 '25	Sale	68.15	8,617	587,275	37,701	Jul 07 04:43 PM
BARRY FLANNELLY	Officer	Jul 03 '25	Proposed Sale	68.15	10,903	743,048		Jul 03 03:10 PM
VIJAY IYENGAR	Officer	Jul 03 '25	Proposed Sale	68.15	8,617	587,272		Jul 03 02:46 PM
SHEILA DENTON	Officer	Jul 02 '25	Proposed Sale	68.61	599	41,097		Jul 02 04:27 PM
Denton Sheila A.	EVP & General Counsel	Jun 03 '25	Option Exercise	58.06	1,795	104,218	28,299	Jun 05 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jun 03 '25	Sale	68.00	1,795	122,060	26,504	Jun 05 04:04 PM
SHEILA DENTON	Officer	Jun 03 '25	Proposed Sale	68.00	1,795	122,060		Jun 03 04:06 PM
Tray Thomas	Principal Accounting Officer	May 30 '25	Sale	65.71	963	63,279	22,654	Jun 03 04:00 PM

BMRN

Biomarin Pharmaceutical Inc

INCY

Incyte Corp

Upgrade your FINVIZ experience